Which country is the targeted drug Axitinib produced in?

Axitinib is a targeted drug mainly used to treat advanced renal cell carcinoma. It interferes with the blood supply of tumors by inhibiting vascular endothelial growth factor receptors (VEGFR) and other related receptors, thereby inhibiting tumor growth and metastasis. Axitinib is developed and produced by the American pharmaceutical company Pfizer (Pfizer).

The research and development of axitinib is led by Pfizer, a large multinational pharmaceutical company headquartered in the United States. Pfizer has long been innovating in the field of tumor treatment, and axitinib, one of its representative targeted drugs, has been widely used clinically. Pfizer's R&D team regards axitinib as one of the key drugs for targeted anti-cancer treatment and has verified its therapeutic effect through meticulous clinical trials.

Axitinib is manufactured by Pfizer at its global manufacturing facilities, including plants in the continental United States and elsewhere. Pfizer strictly follows the Global Good Manufacturing Practice (GMP) during the production process to ensure the quality and safety of each batch of drugs. Axitinib's production and quality control systems are designed to ensure drug purity, stability and efficacy and meet the requirements of global drug regulatory agencies.

Axitinib developed by Pfizer has been approved by the U.S. Food and Drug Administration (FDA) and officially entered the U.S. market in 2012. Axitinib was approved to treat advanced renal cell carcinoma and has shown potential in other cancer types in subsequent clinical studies. FDA’s approval was based on strong clinical trial data demonstrating its significant effect in extending patient survival.

Reference materials:https://en.wikipedia.org/wiki/Axitinib